Stockscreener 앱 받기
74.82
0.88%
0.65
시간 외 거래:
74.82
전일 마감가:
$74.17
열려 있는:
$74
하루 거래량:
288.09K
Relative Volume:
0.65
시가총액:
$1.68B
수익:
$883.37M
순이익/손실:
$71.37M
주가수익비율:
22.32
EPS:
3.3516
순현금흐름:
$150.90M
1주 성능:
+3.21%
1개월 성능:
-4.20%
6개월 성능:
-22.70%
1년 성능:
+15.34%
1일 변동 폭
$73.99
$75.51
1주일 범위
$70.15
$76.00
52주 변동 폭
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(218) 634-3500
주소
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
74.82 | 1.66B | 883.37M | 71.37M | 150.90M | 3.3516 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - TradingView
ANIP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EPS Watch: Can ANI Pharmaceuticals Inc lead its sector in growthQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - TradingView
ANIP PE Ratio & Valuation, Is ANIP Overvalued - Intellectia AI
IBRX Stock Jumps on Progress in NK Cell Therapy Production - TradingView
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak - AlphaStreet
234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP - MarketBeat
Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Ani Pharmaceuticals SVP Cook sells $36k in stock - Investing.com
Ani Pharmaceuticals SVP Cook sells $36k in stock By Investing.com - Investing.com India
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells 3,162 Shares of Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares - MarketBeat
Ani pharmaceuticals SVP Rowland sells $357k in stock By Investing.com - Investing.com South Africa
Ani pharmaceuticals SVP Rowland sells $357k in stock - Investing.com
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan - Stock Titan
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
ANI Pharmaceuticals, Inc. $ANIP Stock Position Reduced by Kennedy Capital Management LLC - MarketBeat
Sizing Up ANI Pharmaceuticals (ANIP) After Recent Share Price Pullback - Yahoo Finance
How ANI’s Reaffirmed 2026 Guidance and Rare Disease Push Will Impact ANI Pharmaceuticals (ANIP) Investors - Sahm
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B - MarketBeat
ANI Pharmaceuticals at Barclays Conference: Rare Disease Focus Drives Growth - Investing.com Canada
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear - MarketBeat
Insider Sell: Krista Davis Sells Shares of ANI Pharmaceuticals I - GuruFocus
ANI Pharmaceuticals (NASDAQ: ANIP) executive sells shares, withholds stock for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) CEO stock withheld to cover taxes - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief sells 6,572 shares under 10b5-1 plan - Stock Titan
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
Insider Moves At ANI Pharmaceuticals Contrast With Valuation Gap And Pullback - Sahm
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com Nigeria
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Insider Trades And Rare Disease Growth Shape ANI Pharmaceuticals Valuation - Yahoo Finance
What ANI Pharmaceuticals (ANIP)'s Strong Q4 Turnaround and Cautious 2026 Outlook Means For Shareholders - Yahoo Finance
Stephen P Carey At ANI Pharmaceuticals Decides to Exercises Options Worth $86K - Benzinga
Mirum Completes Enrollment & Screening in Liver Disease Studies - TradingView
Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best - Yahoo Finance
Stephen Carey Sells 7,312 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ: ANIP) CFO sells shares after option exercise - Stock Titan
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - TradingView
Christopher Mutz Sells 417 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):